Home
Live Updates
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society : vimarsana.com
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Bristol Myers Squibb today announced new interim results from the Phase 3 EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults with schizophrenia. Long-term...
Related Keywords
Italy ,
Roland Chen ,
Bristol Myers Squibb ,
Linkedin ,
Cenexel Hassman Research Institute ,
Instagram ,
Schizophrenia International Research Society ,
Exchange Commission ,
Twitter ,
Facebook ,
Youtube ,
Schizophrenia International Research ,
Myers Squibb ,
Annual Congress ,
Bristol Myers ,
Negative Syndrome Scale ,
Clinical Global Impression Severity ,
Elan Cohen ,
Oral Session ,
New Pharmacological Treatments ,
Delivering Breakthrough Science ,
Meaningful Interventions ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
vimarsana.com © 2020. All Rights Reserved.